This year’s ISPE Biopharmaceutical Manufacturing Conference promises to deliver excellent content and is a must attend for anyone involved in the manufacture of biotech drugs in today’s fast changing environment. Building on the success of our previous conferences this ISPE signature event will cover every aspect from quality, regulatory, drug substance, to drug product, with an emphasis on advanced therapeutic medicinal products including CAR-T, cell and gene therapy, and personalized cancer vaccines. This conference will cover the waterfront from personalized medicines, oligonucleotides, and emerging technologies including continuous manufacturing.
Speakers include industry leaders in manufacturing, quality, regulatory, and academia. This includes prominent FDA speakers from both CBER and CDER. Presentations will be followed by interactive discussions on the challenges and opportunities in truly producing personalized medicines - one patient, one product, covering:
The pharma industry is already under transformation and much more is on the way. Whether you are in a small or large company, start-up or major biopharmaceutical manufacturer, are new or very experienced in the industry, this conference is necessary for you to attend to keep pace with the advancements the industry is bringing in manufacturing technology, newer products, and ultimately patient treatments.
Unlike other Biopharmaceutical manufacturing conferences you may have attended, this conference has a faculty bringing scientific, manufacturing, academic, and health authority experience, and is backed by ISPE’s body of knowledge represented by our expert committees and publications including our Baseline Guides and Good Practice Guides.
There is still time to register however it is getting close so reserve your spot now. If you were waiting for a special invitation, this is it!
In the pharmaceutical industry, which is highly regulated, aseptic processing is a critical component that ensures the sterility of products. Regulators have a set of comprehensive requirements that minimize the risk of contamination. Regulators set the requirements; however, the industry has an obligation to the patients who rely on and expect a drug that is safe and free of contamination....
Like any investment in digital manufacturing systems, demonstrating business payback before and after investment is critical to getting MES projects approved and verifying profitability after investment. Whether it is introducing MES, expanding it to additional sites, switching software, upgrading existing software, or developing electronic production records (EPR) for new drug products,...
Sustainability is emerging as a pivotal force influencing the pharmaceutical industry’s dynamics and steering companies towards transformative change. The focus of this analysis is to delve into the sustainability key performance indicators (KPIs) of prominent pharmaceutical players, namely Pfizer, Sanofi, Glaxo Smith Kline (GSK), Becton Dickinson, Johnson & Johnson, Abbott, Eli Lilly, and...